Clinical Trial Update: IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial of IMA901 in combination with sunitinib for advanced/metastatic renal cell carcinoma has completed. The document does not provide trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• IMA901
• Sunitinib (sunitinib)

Snippet

Sponsor: Immatics Biotechnologies GmbH | Conditions: Metastatic Renal Cell Carcinoma | Phase 3 | Status: COMPLETED